At-home cancer screening kits, particularly those for colon cancer, have gained traction in recent years. “To my knowledge, ...

The global breast cancer therapeutics market is expected to grow from US$ 31.07 billion in 2022 to US$ 63.9 billion by 2030, ...

Northwestern Medicine, Chicago's premier integrated academic health system, and Vitestro, a pioneer in autonomous robotic vascular access and diagnostic blood collection, today announced a multi-year ...

The nonsteroidal anti-inflammatory drug (NSAID) flunixin meglumine has been approved by the FDA for fever associated with ...

Mitolyn is a natural dietary formula developed to promote healthy weight loss in the boy. It boosts the mitochondria levels ...

Good afternoon, and welcome to the Trevi Therapeutics fourth-quarter and year-end 2024 earnings conference call. (Operator Instructions) Please note, this event is being recorded. Various remarks that ...

Babson Diagnostics, a science-first healthcare technology company, has been named in Fast Company's prestigious list of the World's Most Innovative Companies of 2025. Ranked #2 in the healthcare ...

Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor ("TKI”) being jointly developed and commercialized by AstraZeneca and HUTCHMED. In 2023, savolitinib and TAGRISSO ® ...

Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2024 Conference Call.

Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for ...

Q4 2024 Earnings Call Transcript March 17, 2025 FibroGen, Inc. reports earnings inline with expectations. Reported EPS is $-0 ...

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development ...